On August 14th, 2023, VBI ($NASDAQ:VBIV) Vaccines reported their financial results for the second quarter of FY2023, which concluded on June 30th, 2023. The company saw a year-over-year increase of 105.7% in revenue, reaching USD 0.7 million. Net income reported was USD -44.6 million, a slight improvement from the -45.7 million reported in the same period last year.
The market reacted positively to the news, with the company’s stock opening at $1.2 and closing at $1.4, a 7.1% increase from its previous closing price of $1.3. This marked a major turning point for VBI VACCINES, as it had experienced consistent declines in earnings over the past two quarters. The growth in stock prices was further supported by the company’s financials.
Overall, the market responded favorably to VBI VACCINES’ second quarter earnings report and investors appear to be cautiously optimistic about the company’s future outlook. With continued positive momentum, VBI VACCINES is well-positioned to achieve success in the long-term. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Vbi Vaccines. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vbi Vaccines. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vbi Vaccines. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Vbi Vaccines are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Vbi Vaccines Stock Fair Value
GoodWhale conducted an analysis of VBI VACCINES’s financials, and we found that the intrinsic value of the company’s stock was around $45.1. This value was calculated using our proprietary Valuation Line, which takes into account a variety of factors such as cash flow, business operations, and market trends. Currently, VBI VACCINES’s stock is trading at only $1.4, meaning it is dramatically undervalued by 96.9%. This creates an opportunity for investors to purchase this stock at a discount and potentially make a substantial return on their investment. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the vaccine industry is heating up as VBI Vaccines Inc takes on Entasis Therapeutics Holdings Inc, Geovax Labs Inc, and Genocea Biosciences Inc. These companies are all vying for a piece of the pie in an industry that is expected to grow significantly in the coming years. While each company has its own strengths and weaknesses, VBI Vaccines Inc is in a strong position to compete against its rivals.
– Entasis Therapeutics Holdings Inc ($NASDAQ:GOVX)
Geovax Labs Inc is a biotechnology company that focuses on the development of vaccines. The company’s market cap is 20.33M as of 2022 and its ROE is -64.89%. The company’s main products are HIV/AIDS vaccines.
Investors have been pleased with VBI Vaccines’ second quarter financials, which came in much improved from the previous year. Revenue for the quarter was USD 0.7 million, representing a 105.7% year-over-year increase. Net income reported was USD -44.6 million, a slight improvement from the year before.
This news sent the stock price up on the day the earnings were released. Overall, investors appear bullish on the outlook of VBI Vaccines and are optimistic about the future prospects of the company going forward.